Workflow
Animal Health
icon
Search documents
Virbac: in the first half of 2025, revenue recorded solid growth of +5.6% at constant exchange rates and scope of consolidation
Globenewswire· 2025-07-16 15:45
KEY FIGURES Revenue in first half of 2025 €738.3M Growth at constant exchange rates and scope1 +5.6 including companion animals +7.1% farm animals +5.1% Growth at constant exchange rates2 +7.8% Overall change +5.0% Quarterly consolidated revenueOur second-quarter revenue reached €363.1 million, marking a +6.4% increase at constant exchange rates and scope compared to the same period in 2024. This strong quarterly performance demonstrates the resilience of our organic growth, observed acro ...
Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement
Prnewswire· 2025-07-10 12:00
GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance.The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Ela ...
Invest in 4 Winning Stocks With Proven Relative Price Power
ZACKS· 2025-07-09 13:26
Market Overview - The S&P 500 rose by 5% in June, driven by optimism regarding trade deals, a ceasefire in the Middle East, and potential interest rate cuts in 2025 [1] - Positive economic indicators, including strong manufacturing data, increased factory orders, and a favorable jobs report for June, alleviated recession fears [1] July Market Conditions - As July begins, the job market remains robust, inflation is cooling, and companies are set to announce earnings [2] - Trade disagreements may cause short-term market fluctuations, but new trade agreements could provide additional momentum [2] Stock Recommendations - Recommended stocks based on relative price strength include Dell Technologies Inc. (DELL), Jabil Inc. (JBL), Phibro Animal Health Corporation (PAHC), and Hudbay Minerals Inc. (HBM) [3][9] Relative Price Strength Strategy - Investors should assess stocks based on earnings growth and valuation multiples, while also considering their performance relative to industry peers [4] - Underperforming stocks should be avoided, while those outperforming their sectors in price should be prioritized for potential returns [5] Investment Criteria - Stocks that have outperformed the S&P 500 over the past 1, 4, and 12 weeks, along with positive earnings estimate revisions, indicate growth potential [6][8] - A focus on analyst optimism regarding upcoming earnings is crucial, as upward revisions can lead to price gains [7] Screening Parameters - Stocks must show positive relative price changes over 1, 4, and 12 weeks, and have positive current-quarter estimate revisions [8] - Stocks must have a minimum price of $5 and an average 20-day volume of at least 50,000 for adequate liquidity [10] Company Profiles - **Dell Technologies Inc. (DELL)**: Market cap of $84.7 billion, expected EPS growth of 16% year-over-year for fiscal 2026, with a trailing earnings surprise of 2.3% [11][12] - **Jabil Inc. (JBL)**: Expected EPS growth rate of 16.6% over three to five years, with a 102% share price increase in the past year [13][14] - **Phibro Animal Health Corporation (PAHC)**: Market cap of $1.2 billion, expected EPS growth of 71.4% for fiscal 2025, with a 75.7% share price increase in the past year [14][15] - **Hudbay Minerals Inc. (HBM)**: Expected EPS growth rate of 51.7% over three to five years, with a 43.8% year-over-year growth estimate for 2025 and a 17.6% share price increase in the past year [16][17]
Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection
Prnewswire· 2025-07-09 12:27
In Canine Influenza Virus (CIV) studies, TruCan Ultra CIV was shown to be highly effective in protecting dogs' lungs and improving clinical signs: Zero vaccinated dogs developed lung lesions post H3N2 challenge2 100% neutralization of 33 currently circulating CIV field isolates1 Proven to reduce viral shedding2,5 Proven safe across multiple breed and ages in field safety study5 "With the recent USDA approval for TruCan Ultra CIV, Elanco continues to lead the charge in innovative animal health solutions," ...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025
Globenewswire· 2025-07-09 12:00
PORTLAND, Maine, July 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2025. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon aft ...
Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost
Benzinga· 2025-07-07 18:30
Company Overview - JPMorgan upgraded Phibro Animal Health Corporation (PAHC) due to strong execution following its $350 million acquisition of Zoetis' medicated feed additive and water-soluble product portfolio, which includes 37 product lines sold in about 80 countries and six manufacturing sites across the U.S., Italy, and China [1] - The acquisition is expected to enhance Phibro's profitability, improve EBITDA margins, and be accretive to adjusted earnings per share [1] Financial Performance - In Q3 2025, Phibro's sales reached $347.8 million, an increase of $84.6 million, or 32% year over year, although it missed the consensus estimate of $352.40 million [3] - Adjusted earnings for the same period were 63 cents, surpassing the consensus of 52 cents [3] Guidance and Market Outlook - Phibro raised its fiscal 2025 adjusted earnings per share guidance from $1.87-$2.01 to $1.96-$2.09, compared to the consensus of $1.94 [4] - The company revised its sales guidance from $1.25 billion-$1.30 billion to $1.26 billion-$1.29 billion, against a consensus of $1.28 billion [4] - Analyst Knyazkova noted that despite a strong performance in PAHC shares this year, there remains a favorable setup for further upside to estimates and attractive valuation [4] Industry Insights - The animal health performance is expected to exceed expectations for 2025, driven by strong demand, price increases, and healthy growth across medicated feed additives, nutritional specialties, and vaccines for 2026 [2] - While growth in livestock is slower than in companion animals, the livestock sector maintains strong fundamentals, including population growth, rising meat consumption, and limited impact from economic shifts [3]
Phibro Animal Health Stock Up 52.8% in a Year: What's Driving the Rise?
ZACKS· 2025-07-01 13:15
Core Insights - Phibro Animal Health (PAHC) shares have increased by 52.8% over the past year, significantly outperforming the industry growth of 14.3% and the S&P 500's 11.7% gain, indicating strong momentum and solid fundamentals for investors [1][8] Company Overview - Phibro, based in New Jersey, provides a wide range of products for food animals, including poultry, swine, beef, dairy cattle, and aquaculture, while also manufacturing ingredients for personal care, automotive, industrial chemicals, and chemical catalysts [2] Key Growth Drivers - The surge in Phibro's share price is attributed to robust demand for its Animal Health products, with a reported 42% sales growth year over year in the Animal Health segment, driven by a 68% increase in Medicated Feed Additives (MFA) [3][8] - The acquisition of Zoetis' MFA product portfolio has expanded Phibro's offerings by adding over 37 product lines across 80 countries, enhancing its global presence [3][8] - The company has also invested in expanding vaccine manufacturing capacity, including a new facility in Brazil, which has contributed to a 1% revenue increase in the vaccine business for the third quarter of fiscal 2025 [4] Financial Performance - Phibro reported an operating profit of $33.4 million for the fiscal third quarter, marking a 67.8% increase year over year, with an operating margin expansion of 204 basis points [6] - The Mineral Nutrition business grew by 4% year over year, supported by increased sales volume and pricing, while the Performance Products segment benefited from strong demand for personal care ingredients [5] Future Outlook - Earnings per share (EPS) for fiscal 2025 and 2026 are projected to increase by 71.4% and 12.5%, reaching $2.04 and $2.29, respectively, with revenues expected to grow by 25.7% to $1.28 billion in fiscal 2025 [10]
PetVivo (PETV) - 2025 Q4 - Earnings Call Transcript
2025-06-30 22:00
Financial Data and Key Metrics Changes - PetVivo reported a revenue growth of 17% for fiscal year 2025, totaling a record $1,100,000, driven largely by an expanding nationwide distributor network [4][8] - Gross profit was $995,000, representing 87.8% of revenues, which is a decrease from 89.5% in fiscal year 2024 [9] - Operating expenses decreased by 21% to $9,100,000, primarily due to a strategic cost reduction and restructuring program [9] - Net loss improved by 27% to $8,000,000 or $0.39 per share, compared to a net loss of $11,000,000 or $0.78 per share in fiscal year 2024 [10] Business Line Data and Key Metrics Changes - The expanding distributor network contributed $958,000 in sales, accounting for 86% of total revenues [4][8] - The company is focusing on increasing its market share in the companion animal market while maintaining growth in the equine market [4][5] Market Data and Key Metrics Changes - The veterinary healthcare market in Mexico is projected to grow at a 6% CAGR, reaching nearly $2,000,000,000 by 2026 [3] - The U.S. animal health market is projected to double to $11,300,000,000 by 2030, providing significant growth opportunities [19] Company Strategy and Development Direction - The company aims to drive greater adoption of its products, particularly Spring and Precise PRP, by increasing awareness among key decision-makers [12] - Strategic partnerships and collaborations, such as with Digital Landia, are expected to enhance product visibility and market penetration [17][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position to accelerate growth and expand into high-growth markets [19] - The company anticipates strong sales momentum and market penetration in fiscal year 2026, supported by recent advancements and partnerships [18] Other Important Information - The company has strengthened its leadership team and commercial operations, appointing experienced executives to key positions [21][22] - A successful offering of $5,000,000 in Series B convertible preferred stock was completed to support growth strategies [11] Q&A Session Summary Question: How much dilution do you expect from the conversion of the Series B preferred? - The conversion is on a one-to-one basis, with an additional 5,000,000 shares expected if fully converted [28][30] Question: What is the average price per vial of the Spring injection that veterinarians are charging for canines? - The average charge is around $800 per joint, varying between $500 to $1,200 depending on the complexity of the problem [33][35] Question: Can you talk a little bit about the human trials and their projected path? - The company is excited about the results from small and large animal studies, with potential applications in the human market for osteoarthritis, which is valued at approximately $11,200,000,000 in the U.S. [43][44]
Elanco Animal Health (ELAN) Earnings Call Presentation
2025-06-27 07:14
Enriching Life Food and Companionship Investor Overview | May 2025 Notices and Disclaimers Forward-Looking Statements. This presentation contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2025 full year, long-term expectations, our expectations regarding debt levels, and expectations regarding our industry and our operations, performance and financial condition, and i ...
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise
Benzinga· 2025-06-26 18:38
After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated ELAN appears to be turning a corner. What Happened: Investor meetings hosted by William Blair this week gave analysts enough confidence to upgrade the stock, citing a stabilized core business and promising momentum in its innovation pipeline. With new product launches in both livestock and pet health, Elanco is better positioned for growth—though it still faces stiff competition from larger rivals like ...